MRSNMersana Therapeutics Inc
$29.30
$0.04
(0.14%)
Closed $29.08
$0.22
(0.76%)
After Hours
Reported EarningsNov 14
Mkt Cap$145.36M
Vol712,460.00
Fundamentals
Mkt Cap
$145.36M
Volume
-
52W High
$30.39
52W Low
$5.21
PE Ratio
-2.06
Avg. Volume
76,720.00
EPS (Annual)
-$14.12
Rev/Employee
$397,029.41
Earnings
Nov 14
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of "Reduce" from Brokerages
Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has received a consensus rating of "Reduce" from the eight brokerages that are currently covering the stock, Marketbeat Ratings reports. One...
MarketBeat
Halper Sadeh LLC Encourages UDMY, ALEX, UBFO, MRSN Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages UDMY, ALEX, UBFO, MRSN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages UDMY, ALEX, UBFO, MRSN Shareholders to Contact the Firm to...
PR Newswire
Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their...
PR Newswire
Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
Shareholder Alert: The Ademi Firm continues to investigate whether Mersana Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders Shareholder Alert: The Ademi Firm continues to...
PR Newswire
Luminus Management LLC Sells 989,314 Shares of Mersana Therapeutics, Inc. $MRSN
Luminus Management LLC trimmed its stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 95.2% in the third quarter, according to the company in its most recent filing with the...
MarketBeat
683 Capital Management LLC Boosts Stock Position in Mersana Therapeutics, Inc. $MRSN
683 Capital Management LLC lifted its stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN - Free Report) by 20.6% in the second quarter, according to the company in its most recent filing with...
MarketBeat
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN
Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc...
PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR, MRSN, CDTX, and RYI
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR, MRSN, CDTX, and RYI $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--SMLR...
PR Newswire
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Reduce" by Brokerages
Mersana Therapeutics, Inc. (NASDAQ:MRSN - Get Free Report) has earned a consensus recommendation of "Reduce" from the eight brokerages that are presently covering the company, Marketbeat Ratings...
MarketBeat
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest MRSN News
ViewMersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Consensus Rating of "Reduce" from Brokerages
MarketBeat
Halper Sadeh LLC Encourages UDMY, ALEX, UBFO, MRSN Shareholders to Contact the Firm to Discuss Their Rights
PR Newswire
Halper Sadeh LLC Encourages MRSN, CDTX, RYI Shareholders to Contact the Firm to Discuss Their Rights
PR Newswire
Advertisement|Remove ads.